Log in

Relevant bibliographies by topics / 6220f / Journal articles

Journal articles on the topic '6220f'

To see the other types of publications on this topic, follow the link: 6220f.

Author: Grafiati

Published: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '6220f.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hobday, Timothy J., Rui Qin, Diane Lauren Reidy, Malcolm J. Moore, Jonathan R. Strosberg, Andreas Kaubisch, Manisha H. Shah, et al. "Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET)." Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 260. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.260.

Full text

Abstract:

260 Background: Recent placebo-controlled phase III trials of the mTOR inhibitor everolimus and the VEGF/ PDGF receptor inhibitor sunitinib in PNET noted improved progression-free survival (PFS). However, objective response rates (RR) with these agents are <10%. Preclinical studies suggest enhanced anti-tumor effects with combined mTOR and VEGF targeted therapy. Methods: We conducted a phase II trial of the mTOR inhibitor TEM (25 mg IV q week) and the VEGF-A monoclonal antibody BEV (10 mg/kg IV q 2 weeks) in patients (pts) with well or moderately differentiated PNET and progressive disease by RECIST within 7 months of study entry. Co-primary endpoints were RR and 6-month PFS. Planned enrollment is 50 patients, with interim analysis after the first 25 evaluable pts. Pts had no prior mTOR or VEGF targeted agents, ECOG PS 0-1, and adequate hematologic and organ function. Continued octreotide was allowed, but not required. Prior interferon, embolization, and ≤ 2 chemotherapy regimens were allowed. Results: Confirmed PR was documented in 11 of the first 25 (44%) evaluable patients. 20 of 25 (80%) patients were progression-free at 6 months. Both endpoints exceeded pre-defined criteria to continue enrollment. For 35 evaluable patients, the most common grade 3-4 adverse events attributed to therapy were leukopenia (12%), hypertension (12%), hyperglycemia (12%), mucositis (9%), and fatigue (9%). Conclusions: The combination of TEM/BEV has substantial activity in a multi-center phase II trial with RR of 44%, well in excess of single targeted agents in PNET. 6-month PFS was a notable 80% in a population of patients with RECIST criteria progression within 7 months of study entry. Accrual is ongoing. Supported by NCI N01 Contracts: 662205, 62203, 62208, 62209, 62206, 62204, 62207, 62201.

APA, Harvard, Vancouver, ISO, and other styles

2

Cohen, Deirdre Jill, Paul J. Christos, Joseph A. Sparano, Hedy Lee Kindler, Daniel Virgil Thomas Catenacci, Tanios B. Bekaii-Saab, Sanaa Tahiri, et al. "A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 67. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.67.

Full text

Abstract:

67 Background: The HH pathway is overexpressed in gastroesophageal (GE) tumors. Pre-clinically, HH inhibitors have demonstrated a reduction in GE tumor growth, cell motility and invasiveness. V, an oral small-molecule antagonist of the Hh pathway, has previously been safely combined with FOLFOX chemotherapy. Methods: Pts with untreated, metastatic or locally advanced gastric or GEJ adenocarcinoma were randomized 1:1, stratified by institution and disease status (with or w/o distant mets) to FOLFOX (ox 85 mg/m2, LV 200 mg/m2, 5-FU bolus 400 mg/m2, 5-FU infusion 2400 mg/ m2 over 48 hrs) q14d plus V or placebo (P) (150mg PO daily). Cycle defined as 2 weeks and no crossover allowed at progression. FFPET and blood were collected for biomarker analyses. Response assessed every 8 weeks (RECIST 1.1). Primary endpoint was progression-free survival (PFS), secondary objectives were overall survival (OS), response rate (RR), and toxicity. Results: 124 pts (V/P 60/64) enrolled at 20 sites between 10/09-2/12. Pt characteristics (V/P): median age 58/62; ECOG PS 0: 23 (40%) / 30 (47%); male 39 (65%) / 53 (83%); GEJ 37 (62%) / 39 (61%); diffuse histology 20 (43%) / 14 (30%). Median number of FOLFOX cycles 9.5/11. Most common Gr ≥3 toxicities: (% pts V/P) neutropenia 50.0/31.7 (p=0.07), neuropathy 23.1/14.3 (p=0.33), fatigue 15.4/9.5 (p=0.50), thrombosis 13.5/11.1 (p=0.92), anemia 9.6/9.5 (p=0.99), hypokalemia 9.6/4.8 (p=0.52), nausea 7.7/9.5 (p=0.99). Death on or within 30 days of treatment 6.7%/15.6% (p=0.20). Median PFS in ITT population 11.5/9.3 mo (95% CI 8.5-14.4/6.7-11.9; p=0.34) and median OS 12.2/13.9 mo (95% CI 10.2-14.3/11.5-16.3; p=0.48). Non-statistically significant trends toward improved PFS with V were noted in female pts, diffuse histology, and PS 1 (p≤ 0.08). RR (%) 33/27 (p=0.64). Conclusions: Addition of V to FOLFOX did not improve PFS in an unselected advanced GE carcinoma population. Blood and tissue biomarker analyses are ongoing to determine if there is a subset of patients who may derive benefit from V. Supported by: N01-CM-62204, -62201, -62207, -62206, -62209, -62208 and 2UL1 TR000457-06 Clinical trial information: NCT00982592.

APA, Harvard, Vancouver, ISO, and other styles

3

Cohen, Deirdre Jill, Paul J. Christos, Hedy Lee Kindler, Daniel Virgil Thomas Catenacci, Tanios B. Bekaii-Saab, Sanaa Tahiri, Yelena Yuriy Janjigian, et al. "Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 4011. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4011.

Full text

Abstract:

4011 Background: The HH pathway is overexpressed in gastroesophageal (GE) tumors. Pre-clinically, HH inhibitors have demonstrated a reduction in GE tumor growth, cell motility and invasiveness. V, an oral small-molecule antagonist of the Hh pathway, has previously been safely combined with FOLFOX chemotherapy. Methods: Pts with untreated metastatic or locally advanced gastric or GEJ adenocarcinoma were randomized 1:1, stratified by institution and disease status (with or w/o distant mets) to FOLFOX (ox 85 mg/m2, LV 200 mg/m2, 5-FU bolus 400 mg/m2, 5-FU infusion 2400 mg/ m2 over 48 hrs) q14d plus V or placebo (P) (150mg PO daily). Cycle defined as 2 weeks and no crossover allowed at progression. FFPET and blood were collected for biomarker analyses. Response assessed every 8 weeks (RECIST 1.1). Primary endpoint was progression-free survival (PFS), secondary objectives were overall survival (OS), response rate (RR), and toxicity. Results: 124 pts enrolled at 20 sites between 10/09-2/12. 123 pts eligible for analysis (V/P 60/63). Pt characteristics (V/P): median age 58/62; ECOG PS 0: 24 (40%) / 30 (48%); male 39 (65%) / 52 (83%); GEJ 37 (62%) / 39 (61%); diffuse or mixed histology 19 (32%) / 10 (16%), recurrent disease 10(17%) / 16 (25%). Median number of FOLFOX cycles 10/11. Most common Grade ≥3 toxicities: (% pts V/P) neutropenia 50/32 (p=0.07), neuropathy 19/13 (p=0.49), fatigue 15/10 (p=0.50), thrombosis 14/11 (p=0.92), anemia 10/10 (p=0.99), hemorrhage-GI 8/11 (p=0.77), hypokalemia 10/5 (p=0.76), nausea 8/8 (p=0.99). Death on or within 30 days of treatment 6.7%/15.6% (p=0.20). Median PFS in intent to treat population 7.3/8.0 mo (95% CI 4.6-10.1/5.1-11.0; p=0.64) and median OS 11.5/14.9 mo (95% CI 9.6-13.4/11.3-18.4; p=0.23). Overall RR (%) 35/35 (p=0.99). Conclusions: Addition of V to FOLFOX did not improve PFS in an unselected advanced GE carcinoma population. Blood and tissue biomarker analyses are ongoing to determine if there is a subset of patients who may derive benefit from V. Supported by: N01-CM-62204, -62201, -62207, -62206, -62209, -62208 and 2UL1 TR000457-06. Clinical trial information: NCT00982592.

APA, Harvard, Vancouver, ISO, and other styles

4

Morgan, Robert, Amit M. Oza, Rui Qin, Briant Fruth, Hal Hirte, Helen Mackay, Daliah Tsoref, et al. "A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 5517. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5517.

Full text

Abstract:

5517 Background: Anti-angiogenic therapy is active in OC; the combination of VEGF and mTOR inhibitors is hypothesized to further improve activity. This report is the OC cohort of a multi-histology phase II study assessing the activity and toxicity of B/T. Methods: Patients (Pts) with recurrent epithelial OC who had received ≤ 2 chemotherapy regimens and no prior treatment with a VEGF or mTOR inhibitor were eligible. A two-stage design was used with second stage accrual if >6 pts had objective responses (OR) or >10 pts of the first 25 remained progression-free (PF) at six months (mo). Pre-defined end-points for a recommendation for further clinical trial evaluation included at least 15/50 with OR or 26/50 PF at six mo. Treatment included T 25 mg IV wkly and B 10 mg/kg IV q14 days on 28 day cycles. Results: 58 pts were enrolled (the first 50 pts are used to determine a final recommendation). Median age=62 (range 35-82). A median of 4 (range 1-23) cycles were administered. 24 were platinum-sensitive, 34 resistant. Off-study reasons included 13 adverse events and disease progression in 38. 3 refused further therapy due to toxicity. 14 of the first 50 pts had partial response (PR) (9 platinum-resistant); 25/50 remained PF (8 PR, 15 SD, 2 non-progressing) at 6 mo. Grade (gr) 3/4 toxicities occurring >2 events include: fatigue (4), stomatitis (7), hypertension (5), neutropenia (4), thrombocytopenia (4), hypokalemia (3). One rectal and one vaginal fistula, and two colonic perforations (one gr 2 and one gr 3 during cycles 3 and 1 respectively) were observed. Episodes of gr 1/2 oral, nasal, pulmonary, vaginal and gastrointestinal hemorrhage were also observed. Conclusions: Although the OR and PFS did not reach pre-defined standards, the numbers of OR and 6 mo PFS suggest potential enhanced activity with a combination of mTOR inhibitor with anti-angiogenic therapy. Other combinations of these targeted agents may result in more satisfactory activity with less toxicity. N01-CM-62203 (PMH) N01-CM-62208 (Southeast Phase 2) N01 CM-62209 (CCCP) N01-CM-62204 (NYCC) N01-CM-2011-0071C (Chicago) N01-CM62205 (Mayo) Clinical trial information: NCT01010126.

APA, Harvard, Vancouver, ISO, and other styles

5

Ramalingam, S. S., M. Maitland, P. Frankel, A. E. Argiris, M. Koczywas, B. Gitlitz, I. Espinoza-Delgado, E. E. Vokes, D. R. Gandara, and C. P. Belani. "Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 8004. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.8004.

Full text

Abstract:

8004 Background: Vorinostat, a HDAC inhibitor, enhances paclitaxel and platinum-mediated anti-cancer activity in preclinical studies by enhanced tubulin acetylation and DNA fragmentation respectively. Promising activity with carboplatin (C), paclitaxel (P), and vorinostat in patients with advanced NSCLC in the phase I study (Ramalingam et al, Clin Cancer Res, 2007) prompted this placebo-controlled, randomized phase II study. Methods: Pts. with stage IIIB (wet) or IV NSCLC, performance status (PS) 0/1, no prior therapy and adequate bone marrow, renal and hepatic function were randomized (2:1) for therapy with PC with either vorinostat or placebo. Treatment consisted of C: AUC=6 mg/ml.min; and P 200 mg/m2 both given on day 3 along with either vorinostat (400 mg PO QD) or placebo on days 1–14 of each 3 wk cycle to a maximum of 6 cycles. The estimated sample size to demonstrate a 50% improvement in response rate for vorinostat over placebo was 93 pts. (one-sided P, type I error 10%). Results: Ninety-four pts. were enrolled (vorinostat-64; placebo-32). Pts. baseline characteristics were similar between the two arms (median age 64, male 60%, PS 0 40%, brain mets 16%). Median # cycles: vorinostat-3.5; placebo - 4. The confirmed response rate was superior with vorinostat over placebo (34% vs. 12.5%, P = 0.02). At the time of analysis, the preliminary median PFS for vorinostat and placebo were 5.75 and 4.1 m respectively (ITT). Follow up for survival is ongoing. Common grade 3/4 toxicities (vorinostat vs. placebo): neutropenia (44% vs. 47%); thrombocytopenia (33% vs. 16%); fatigue (13% vs. 3%); hyponatremia (21% vs. 6%); diarrhea (5% vs. 0). Discontinuation from study after cycle 1 was higher with vorinostat (27% vs. 16%). Biomarker studies on baseline tumor tissue and peripheral blood cells are ongoing. Conclusions: Administration of vorinostat with carboplatin and paclitaxel resulted in a significantly superior response rate for pts.with advanced NSCLC. HDAC inhibition is a novel therapeutic strategy for treatment of NSCLC. Supported by ASCO Career Development Award to S.S.Ramalingam, and NCI NO1-CM-62209, NO1-CM-62201, NO1-CM-62208. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

6

Nedashkovskaya, Olga I., Seung Bum Kim, Dong Sung Shin, Irina A. Beleneva, and Valery V. Mikhailov. "Fulvivirga kasyanovii gen. nov., sp. nov., a novel member of the phylum Bacteroidetes isolated from seawater in a mussel farm." International Journal of Systematic and Evolutionary Microbiology 57, no. 5 (May 1, 2007): 1046–49. http://dx.doi.org/10.1099/ijs.0.64641-0.

Full text

Abstract:

A novel, strictly aerobic, heterotrophic, gliding, Gram-negative, oxidase-, catalase-, β-galactosidase- and alkaline phosphatase-positive marine bacterium, designated strain KMM 6220T, was isolated from seawater and studied by using a polyphasic taxonomic approach. The DNA G+C content of strain KMM 6220T was 59.9 mol%. The predominant fatty acids were iso-C15 : 1, iso-C15 : 0, iso-C15 : 0 3-OH, iso-C17 : 0 3-OH and C16 : 1 ω7/iso-C15 : 0 2-OH. Phylogenetic analysis based on 16S rRNA gene sequencing revealed that strain KMM 6220T formed a cluster with the misclassified strains [Flexibacter] aggregans NBRC 15974 and [Flexibacter] tractuosus NBRC 16035 and with the type strains of Reichenbachiella agariperforans and Roseivirga ehrenbergii with levels of similarity of 95.9, 94.4, 92.0 and 91.8 %, respectively. On the basis of its phenotypic, chemotaxonomic, genotypic and phylogenetic characteristics, strain KMM 6220T is considered to represent a novel species of a new genus in the phylum Bacteroidetes, for which the name Fulvivirga kasyanovii gen. nov., sp. nov. is proposed. The type strain of the type species is KMM 6220T (=CCTCC AB 206119T=KCTC 12832T).

APA, Harvard, Vancouver, ISO, and other styles

7

PODHORN??, J., and KR??IAKM. "FANANSERIN (RR 62203), A POSSIBLE NOVEL ATYPICAL ANTIPSYCHOTIC?" Behavioural Pharmacology 7, Supplement 1 (May 1996): 89. http://dx.doi.org/10.1097/00008877-199605001-00202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Doble, A., O. Ferris, E. Heuillet, J. Ménager, and J. C. Blanchard. "3H-RP 62203: IN VITRO 5-HT2 BINDING STUDIES." Clinical Neuropharmacology 15 (1992): 581B. http://dx.doi.org/10.1097/00002826-199202001-01132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Malgouris, Christiane, Fabienne Flamand, and Adam Doble. "Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. Pharmacological characterization of [3H]RP 62203 binding in the rat brain." European Journal of Pharmacology 233, no. 1 (March 1993): 37–45. http://dx.doi.org/10.1016/0014-2999(93)90346-j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pinheiro, Gilson de Assis, Sérgio Henrique de Souza Alves, Pedro Paulo Murce, and Antonio Pedro de Mello Cruz. "Envolvimento dos receptores 5-HT2 da amígdala nos níveis de ansiedade induzidos pela exposição de ratos ao labirinto em cruz elevado." Psicologia: Teoria e Pesquisa 18, no. 3 (December 2002): 329–35. http://dx.doi.org/10.1590/s0102-37722002000300013.

Full text

Abstract:

O efeito de microinjeções intra-amigdalóides do antagonista 5-HT2A/2C de receptores serotoninérgicos RP 62203 (1,0; 2,5; 5,0 mg) foi investigado em medidas tradicionais e etológicas (esquadrinhar, espreitar e explorações da extremidade) de ansiedade de ratos no labirinto em cruz elevado. A dose de 5,0 mg aumentou as porcentagens de entrada e de tempo nos braços abertos, sem alterar no número de entradas nos braços fechados. As categorias esquadrinhar, espreitar e explorações da extremidade também foram alteradas pela droga. As doses de 2,5 e 5,0 mg aumentaram o tempo gasto em esquadrinhar e diminuíram o tempo gasto em espreitar. O número de explorações da extremidade também foi aumentado pela injeção da droga na dose de 5,0 mg. Este padrão comportamental sugere um efeito ansiolítico do RP 62203. A participação dos receptores 5-HT2A/2C da amígdala na regulação desse efeito é discutida.

APA, Harvard, Vancouver, ISO, and other styles

11

Tang, Liang, Yunliang Jiang, and Jungang Lou. "Reliability Architecture for Collaborative Robot Control Systems in Complex Environments." International Journal of Advanced Robotic Systems 13, no. 1 (January 2016): 17. http://dx.doi.org/10.5772/62201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

El-Batal, Ahmed Ibrahim, Fatma Abd El-Lateef Gharib, Safia Mohammed Ghazi, Amal Zakaria Hegazi, and Asmaa Gamal Mohamed Abd El Hafz. "Physiological Responses of Two Varieties of Common Bean (Phaseolus VulgarisL.) to Foliar Application of Silver Nanoparticles." Nanomaterials and Nanotechnology 6 (January 2016): 13. http://dx.doi.org/10.5772/62202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Zhu, Qiuguo, Yichao Mao, Rong Xiong, and Jun Wu. "Adaptive Torque and Position Control for a Legged Robot Based on a Series Elastic Actuator." International Journal of Advanced Robotic Systems 13, no. 1 (January 2016): 26. http://dx.doi.org/10.5772/62204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Stutzmann, J. M., B. Eon, M. Roux, M. Lucas, J. C. Blanchard, and P. M. Laduron. "RP 62203, a 5HT2 antagonist, enhances slow wave sleep in rats." European Journal of Pharmacology 183, no. 4 (July 1990): 1394. http://dx.doi.org/10.1016/0014-2999(90)94522-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Kaspi, Victoria M., R. N. Manchester, Simon Johnston, A. G. Lyne, and N. D'Amico. "PSR J1341-6220 - A young pulsar in a supernova remnant." Astrophysical Journal 399 (November 1992): L155. http://dx.doi.org/10.1086/186630.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Stutzmann, Jean-Marie, Bertrand Eon, Michelle Lucas, Jean-Charles Blanchard, and PierreM Laduron. "RP 62203, A 5-Hydroxytryptamine2 Antagonist, Enhances Deep NREM Sleep in Rats." Sleep 15, no. 2 (March 1992): 119–24. http://dx.doi.org/10.1093/sleep/15.2.119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Doble, A., D. Girdlestone, O. Piot, D. Allam, J. Betschart, A. Boireau, A. Dupuy, et al. "Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist." British Journal of Pharmacology 105, no. 1 (January 1992): 27–36. http://dx.doi.org/10.1111/j.1476-5381.1992.tb14206.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Koch, Claudia, Stefan Hertwig, and Bernd Appel. "Nucleotide Sequence of the Integration Site of the Temperate Bacteriophage 6220, Which Carries the Shiga Toxin Gene stx1ox3." Journal of Bacteriology 185, no. 21 (November 1, 2003): 6463–66. http://dx.doi.org/10.1128/jb.185.21.6463-6466.2003.

Full text

Abstract:

ABSTRACT The integration site, attR, of the Shiga toxin-encoding phage 6220 (stx 1ox3) has been determined. The phage integrates into the chromosome of its Escherichia coli host strain, CB6220, within a gene that is homologous to gene Z2577 and encodes an oxidoreductase. This new integration site was found in different Stx1ox3-producing enterohemorrhagic E. coli strains, which were analyzed by PCR.

APA, Harvard, Vancouver, ISO, and other styles

19

Wang, Na, R. N. Manchester, R. Pace, M. Bailes, V. M. Kaspi, B. W. Stappers, and A. G. Lyne. "Glitches in Southern Pulsars." International Astronomical Union Colloquium 177 (2000): 109–10. http://dx.doi.org/10.1017/s0252921100059194.

Full text

Abstract:

AbstractParkes timing observations of 31 mostly young pulsars over nearly nine years are described. A total of 29 glitches were detected, of which 19 are previously unreported. Twelve glitches were seen in PSR J1341–6220, making this the most frequently glitching pulsar known, and the largest known glitch was detected in PSR J1614–5047. Distributions of glitch parameters were investigated.

APA, Harvard, Vancouver, ISO, and other styles

20

Dhasmana, Swati, Anupam Dhasmana, Stella Rios, Iris A. Perez, Sheema Khan, Farrukh Afaq, Upender Manne, Murali M. Yallapu, and Subhash C. Chauhan. "Abstract 6220: TRIP13 augments pancreatic cancer progression- An integrated systems biology study." Cancer Research 84, no. 6_Supplement (March 22, 2024): 6220. http://dx.doi.org/10.1158/1538-7445.am2024-6220.

Full text

Abstract:

Abstract Background- Pancreatic cancer (PanCa) is one of the most aggressive forms of cancer and its incidence rate is continuously increasing every year. It is expected that by 2030, PanCa will become the 2nd leading cause of cancer related deaths in the United States due to the lack of understanding of the complexity of disease, early diagnostic methods, and extremely poor survival. Despite great advancements in biomedical research, there are very limited modalities available for the early detection of PanCa and its treatment. Thus, understanding of disease biology and identification of newer diagnostic and therapeutic modalities are high priority research in the field. Our group has identified Thyroid Receptor Interacting Protein -13 (TRIP13) as an oncogenic protein which contributes to early events of PanCa. Methodology- High dimensional omics and structural elucidation of TRIP13 was conducted using publicly available databases like Consurf, Phosphosite, GTEx and GEPIA2. Molecular biology techniques were applied to cross validate all our bioinformatics data. qPCR, immunoblotting and IHC analysis was performed in progressive PDAC cell lines and human tissues to decipher the expression level of TRIP13 in various pathological staging including functional enrichment analysis using Linkdomics. Results- The structural elucidation analysis revealed that most of the functionally exposed residues, phosphorylation and ubiquitylation sites situated at AAA domain of TRIP13. As compared to normal, TRIP13 is significantly over expressed in pancreatic tumor samples. Pathological staging 2 and 1 (early stages) showed relatively higher expression of TRIP13 as compared advanced stage. Of the total 7 isoforms of TRIP13, only one isoform (TRIP13-001) has shown the over expression in pancreatic tumor samples and shown association with poor survival. In correlation studies, TRIP13 has shown positive association with other pancreatic cancer biomarkers (CEACAM5, S100A4, MUC1, MSLN, CA125). The functional enrichment analyses suggest that TRIP13 is involved in important patho-physiological pathways like DNA repair, viral carcinogenesis, cellular senescence, and cell cycle. Our wet lab experiments also support our computational biology observation. Conclusion- This integrated computational biology study suggests a potential role of TRIP13 in pancreatic cancer progression via modulation of important oncological pathways. Wet lab experimentations also validated the involvement of TRIP13 in pancreatic cancer progression. TRIP13 expression may be associated with patient prognosis. Thus, its inhibitory small molecules can be useful for boosting pancreatic cancer therapies in clinical settings. Key words- TRIP13, Pancreatic cancer, Early events of cancer, Integrative Biology, Transcriptomics, Computational biology Citation Format: Swati Dhasmana, Anupam Dhasmana, Stella Rios, Iris A. Perez, Sheema Khan, Farrukh Afaq, Upender Manne, Murali M. Yallapu, Subhash C. Chauhan. TRIP13 augments pancreatic cancer progression- An integrated systems biology study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6220.

APA, Harvard, Vancouver, ISO, and other styles

21

Kirby, Zamyat. "Dir: Farouk Ubaysi . Prod: Nazir Khaja and Bashir Matin for Islamic Information Services, PO Box 6220. Altadena, CA 91003-6220. Tel: 800-531-4447. Fax: 818-791-9824." Middle East Studies Association Bulletin 31, no. 2 (December 1997): 198–99. http://dx.doi.org/10.1017/s0026318400035951.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Heuillet, Edith, François Petitet, Serge Mignani, Jean-Luc Malleron, Jacques Lavayre, Gervais Néliat, Adam Doble, and Jean-Charles Blanchard. "The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor." European Journal of Pharmacology 314, no. 1-2 (October 1996): 229–33. http://dx.doi.org/10.1016/s0014-2999(96)00554-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lever, John R., and Suzanne M. Johnson. "Synthesis of a radioiodinated analogue of the serotonin 5-HT2A receptor ligand RP 62203." Journal of Labelled Compounds and Radiopharmaceuticals 41, no. 2 (February 1998): 143–50. http://dx.doi.org/10.1002/(sici)1099-1344(199802)41:2<143::aid-jlcr63>3.0.co;2-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

PEDRIALI, LUCA, MAURIZIO SOSSO, and BRUNO DELL’ANGELO. "Naticid gastropods from the middle Miocene of western Ukraine." Zootaxa 4700, no. 2 (November 19, 2019): 151–95. http://dx.doi.org/10.11646/zootaxa.4700.2.1.

Full text

Abstract:

The paper covers 11 species of naticid gastropods occurring in the lower Serravallian (Upper Badenian) strata of western Ukraine (Central Paratethys). The studied material (over 1,700 naticids) represents six genera and 11 species, of which eight are new: Cochlis odovychenorum, Cochlis ukrainensis, Tectonatica anistratenkorum, Tectonatica pseudoprietoi, Euspira sirenkoi, Payraudeautia ermesi, Payraudeautia sabrinae and Payraudeautia varovtsiana. Additionally, we have also identified Euspira protracta (Eichwald, 1830), Polinices staszici (Friedberg, 1923) and Sinum affinis (Eichwald, 1830). A lectotype of Sinum affinis is designated (ZISP 1/62208). Detailed descriptions of the protoconch and teleoconch morphology of the taxa involved, including SEM images, are presented.

APA, Harvard, Vancouver, ISO, and other styles

25

Wolfe, Rachel M., Al‐Walid Mohsen, Cate Walsh Vockley, Carol A. Bertrand, Robert D. Nicholls, Paige Heiman, Leah M. Seibold, Jerry Vockley, and Lina Ghaloul‐Gonzalez. "Novel GUCY2C variant causing familial diarrhea in a Mennonite kindred and a potential therapeutic approach." American Journal of Medical Genetics Part A 185, no. 7 (May 5, 2021): 2046–55. http://dx.doi.org/10.1002/ajmg.a.62207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Robin, Nathaniel H. "Choose your words carefully." American Journal of Medical Genetics Part A 185, no. 7 (April 8, 2021): 1953. http://dx.doi.org/10.1002/ajmg.a.62206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Roebke, Logan J., Josh W. Vander Maten, and Ghattas Alkhoury. "Hyperbaric oxygen management of recurrent cellulitis in poikiloderma with neutropenia." American Journal of Medical Genetics Part A 185, no. 7 (April 9, 2021): 2150–52. http://dx.doi.org/10.1002/ajmg.a.62204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Wang, Raymond Yu‐Jeang. "To John M. Graham Jr, who called me into a career in clinical genetics." American Journal of Medical Genetics Part A 185, no. 9 (April 12, 2021): 2646–48. http://dx.doi.org/10.1002/ajmg.a.62200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

De Luca, Chiara, Simonetta Picone, Matteo Cassina, Simone Marziali, Silvia Morlino, Letizia Camerota, Gianpiero Tamburrini, et al. "Craniosynostosis is a feature of CHD7 ‐related CHARGE syndrome." American Journal of Medical Genetics Part A 185, no. 7 (April 12, 2021): 2160–63. http://dx.doi.org/10.1002/ajmg.a.62208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Rosenfeld, Jill A., Rui Xiao, Mir Reza Bekheirnia, Farah Kanani, Michael J. Parker, Mary K. Koenig, Arie Haeringen, et al. "Heterozygous variants in SPTBN1 cause intellectual disability and autism." American Journal of Medical Genetics Part A 185, no. 7 (April 13, 2021): 2037–45. http://dx.doi.org/10.1002/ajmg.a.62201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Coulie, Richard, Dmitriy M. Niyazov, Michael J. Gambello, Elodie Fastré, Pascal Brouillard, and Miikka Vikkula. "Hypotrichosis‐lymphedema‐telangiectasia syndrome: Report of ileal atresia associated with a SOX18 de novo pathogenic variant and review of the phenotypic spectrum." American Journal of Medical Genetics Part A 185, no. 7 (April 14, 2021): 2153–59. http://dx.doi.org/10.1002/ajmg.a.62205.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ülgen Tekerek, Nazan, Başak Nur Akyıldız, and Muammer Hakan Poyrazoğlu. "Comparison Between Dead Space/Tidal Volume and Work of Breathing in Predicting Extubation Failure in Critically Ill Children." Turkish Journal of Pediatric Emergency and Intensive Care Medicine 5, no. 1 (April 5, 2018): 1–5. http://dx.doi.org/10.4274/cayd.62207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Szubert, Sebastian, Artur Łojewski, Rafał Moszyński, Arkadiusz Lisowski, Stefan Sajdak, and Dariusz Szpurek. "Ultrasonographic features and CA125 levels of hormonally active ovarian tumors." Polish Gynaecology 87, no. 04 (2016): 254–59. http://dx.doi.org/10.17772/gp/62201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kulik-Rechberger, Beata, Artur Kościesza, Elżbieta Szponar, and Justyna Domosud. "Hepcidin and iron status in pregnant women and full-term newborns in first days of life." Polish Gynaecology 87, no. 04 (2016): 288–92. http://dx.doi.org/10.17772/gp/62202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kurzawińska, Grażyna, Magdalena Barlik, Krzysztof Drews, Agata Różycka, Agnieszka Seremak-Mrozikiewicz, Marcin Ożarowski, Andrzej Klejewski, Bogusław Czerny, and Hubert Wolski. "Coexistence of ACE (I/D) and PAI-1(4G/5G) gene variants in recurrent miscarriage in Polish population." Polish Gynaecology 87, no. 04 (2016): 271–76. http://dx.doi.org/10.17772/gp/62203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Trenkić, Milan, Jasmina Popović, Vesna Kopitović, Artur Bjelica, Radomir Živadinović, and Sonja Pop-Trajković. "Flexible GnRH antagonist protocol vs. long GnRH agonist protocol in patients with polycystic ovary syndrome treated for IVF: comparison of clinical outcome and embryo quality." Polish Gynaecology 87, no. 04 (2016): 265–70. http://dx.doi.org/10.17772/gp/62205.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Zawiejska, Agnieszka, Ewa Wender-Ożegowska, and Jacek Brązert. "Chronic and gestational metabolic disorders have a different impact on late-pregnancy endothelial function in pregnant women." Polish Gynaecology 87, no. 04 (2016): 283–87. http://dx.doi.org/10.17772/gp/62209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Coloma, J. F., L. R. Valverde, and M. García. "Estimación de los costes de construcción de viviendas rústicas mediante Redes Neuronales Artificiales." Informes de la Construcción 71, no. 554 (July 3, 2019): 293. http://dx.doi.org/10.3989/ic.62206.

Full text

Abstract:

La Administración Pública y el promotor privado buscan tener un conocimiento previo de los costes de cualquier edificación. Existen en la literatura numerosas metodologías que permiten realizar la valoración de un inmueble, pero siempre se ha realizado para viviendas urbanas en ciudades grandes o medianas. Esta investigación propone el uso de Inteligencia Artificial para el estudio de viviendas rústicas en pequeñas ciudades como la de Cáceres (España). La investigación propone un procedimiento de Redes Neuronales Artificiales (RNA) para conseguir por un lado estimar a través de un método automático el coste de construcción de la vivienda rústica y por otro, identificar los atributos más determinantes en su precio final. La RNA diseñada establece como variables más influyentes en el precio final del inmueble los espacios húmedos (baños y cocina), la superficie construida y la antigüedad por este orden, diferenciándose de las variables más determinantes en el precio de las viviendas urbanas en grandes o medianas ciudades que son la superficie construida y su ubicación.

APA, Harvard, Vancouver, ISO, and other styles

39

Sanchez‐Lara, Pedro A., Katheryn Grand, Maria K. Haanpää, Cynthia J. Curry, Raymond Wang, Fatih Ezgü, Catherine M. Rose, et al. "Thinking outside “The Box”: Case‐based didactics for medical education and the instructional legacy of Dr John M. Graham, Jr." American Journal of Medical Genetics Part A 185, no. 9 (April 29, 2021): 2636–45. http://dx.doi.org/10.1002/ajmg.a.62202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Di Fede, Elisabetta, Angela Peron, Elisa Adele Colombo, Cristina Gervasini, and Aglaia Vignoli. "SLC35F1 as a candidate gene for neurodevelopmental disorders resembling Rett syndrome." American Journal of Medical Genetics Part A 185, no. 7 (April 5, 2021): 2238–40. http://dx.doi.org/10.1002/ajmg.a.62203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ergen, Hüseyin, and Ferdi ÇOKKESER. "ÖZEL OKUL ÖĞRETMENLERİNİN YAŞADIĞI SORUNLAR." Uluslararası İnovatif Eğitim Araştırmacısı CİLT 2 SAYI 1, CİLT 2 SAYI 1 (2022): 111–36. http://dx.doi.org/10.29228/iedres.62209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Özdemir, Fulya, and Ayten AKATAY. "Zamansal Motivasyon Teorisi Ve Erteleme Davranışı." Social Sciences Studies Journal 98, no. 98 (2022): 1664–73. http://dx.doi.org/10.29228/sssj.62201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

SUCU, Hakan, and Recep BOZYİĞİT. "Akıllı Botanik Park Uygulamasının Ortaöğretim Öğrenci Görüşlerine Göre Değerlendirilmesi." Social Sciences Studies Journal 98, no. 98 (2022): 1654–63. http://dx.doi.org/10.29228/sssj.62200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kesgin, Makbule Tokur. "EDİTÖRDEN: Etki Büyüklüğü Gerekli mi?" Yaşam Boyu Hemşirelik Dergisi 1, no. 1 (2022): i—v. http://dx.doi.org/10.29228/llnursing.62208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Husser, Daniela, Vincent Pellissier, Sven Hohenstein, Laura Ueberham, Sebastian König, Gerhard Hindricks, Andreas Meier‐Hellmann, Ralf Kuhlen, and Andreas Bollmann. "Hospital care of patients with inherited cardiomyopathies in Germany during the Covid‐19 pandemic insights from the German‐wide Helios hospital network." American Journal of Medical Genetics Part A 185, no. 7 (April 19, 2021): 2278–82. http://dx.doi.org/10.1002/ajmg.a.62209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Çaltık Yılmaz, Aysun, and Sevgi Başkan. "İlköğretim ve Lise Öğrencilerinin AIDS’e İlişkin Bilgilerinin Değerlendirilmesi." Güncel Pediatri 12, no. 1 (April 5, 2014): 9–15. http://dx.doi.org/10.4274/jcp.62207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Çonkar, Seçil, Recep Sancak, and Canan Aygün. "The Role of Neonatal Sepsis in the Development of Allergic Diseases in Childhood." Journal of Pediatric Research 3, no. 4 (December 1, 2016): 175–79. http://dx.doi.org/10.4274/jpr.62207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Babayiğit, Münire, Zehra Baykal Tutal, Necla Dereli, Handan Güleç, Mustafa Alparslan Babayiğit, and Eyüp Horasanlı. "Are We Being Informed Correctly During the Patient Transfer to the Intensive Care Units?" Türk Yoğun Bakım Derneği Dergisi 14, no. 2 (August 11, 2016): 54–58. http://dx.doi.org/10.4274/tybdd.62207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

MOHAMMADI NEJAD, Solmaz, Hilal ÖZGÜNEŞ, and Nursen BAŞARAN. "Pharmacological and Toxicological Properties of Eugenol." Turkish Journal of Pharmaceutical Sciences 14, no. 2 (August 1, 2017): 201–6. http://dx.doi.org/10.4274/tjps.62207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Ceran, Dilek, and Kemalettin Deniz. "TEOG Sınavı Sorularının Okuma Becerisiyle Çözülebilme Düzeyi." Ana Dili Eğitimi Dergisi 3, no. 2 (April 26, 2015): 92. http://dx.doi.org/10.16916/aded.62200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!